Regeneron Pharmaceuticals, Inc. (REGN)
Why Dupixent Keeps Regeneron A Top Big Pharma Pick
Regeneron Pharmaceuticals ended 2025 and started this year on a high note. Regeneron and its partner Sanofi are among the leaders in the immune-mediated inflammatory diseases market. In Q4, Dupixent sales grew 22.8% year-on-year and 2.2% quarter-on-quarter to about €4.25 billion.
1 No-Brainer Biotech Stock To Buy Today and Never Sell
This biotech company has a track record of commercializing products and delivering growth. It also has strengths in research and development.
Will Eylea Sales Decline Weigh on REGN's Top Line in 2026?
Regeneron foresees further Eylea decline in 2026 as biosimilars loom, but Eylea HD, Dupixent and Libtayo aim to steady revenues.
Regeneron: Expect Double-Digit Growth In 2026
Regeneron is poised for double-digit revenue and EPS growth in 2026, driven by Dupixent and reduced Eylea headwinds. Dupixent's robust expansion and pipeline successors support Regeneron's long-term growth and mitigate post-exclusivity risks. Eylea's decline is moderating, aided by increased patient support and anticipated label expansions.
Regeneron Pharmaceuticals, Inc. (REGN) Q4 2025 Earnings Call Transcript
Regeneron Pharmaceuticals, Inc. (REGN) Q4 2025 Earnings Call Transcript
Regeneron bets added cholesterol benefit will help its obesity drug stand out
Regeneron Pharmaceuticals' executives voiced confidence in its experimental weight-loss drug on Friday, saying added cholesterol-lowering benefits could give the company an edge in an increasingly crowded obesity market.
Regeneron (REGN) Reports Q4 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Regeneron (REGN) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
REGN Q4 Earnings Beat Estimates, Sales Rise on Eylea HD Growth
REGN beats Q4 earnings estimates as Eylea HD and Dupixent profits lift revenues, though higher expenses drive a year-over-year EPS decline.
Regeneron (REGN) Q4 Earnings and Revenues Beat Estimates
Regeneron (REGN) came out with quarterly earnings of $11.44 per share, beating the Zacks Consensus Estimate of $10.56 per share. This compares to earnings of $12.07 per share a year ago.
Will Higher Dupixent Profits, Eylea HD Sales Drive REGN's Q4 Earnings?
REGN's Q4 report could hinge on Dupixent profit growth and strong Eylea HD uptake as legacy Eylea sales face competitive pressure.
Regeneron: Q4 Earnings Preview - Why I'm Expecting A Beat And Strong 2026
Regeneron Pharmaceuticals, Inc. is approaching a pivotal earnings report following a strong JP Morgan Healthcare Conference update. I maintain a Buy rating on REGN, supported by a >16% share price gain since my last note. Despite recent gains, REGN trades well below its ~$1,200 all-time high from August 2024.
REGN or ILMN: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Regeneron (REGN) and Illumina (ILMN). But which of these two stocks presents investors with the better value opportunity right now?
